Arca
Skip to content
Tools
Tools

Primary biliary cholangitis (PBC)

Drug research and approvals for primary biliary cholangitis (PBC): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 33 studies of primary biliary cholangitis (PBC) are recruiting on ClinicalTrials.gov, Health Canada has authorized 18 drug trials for it since 2013, FDA has 3 approved and 12 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 33
  • Trials authorized in Canada: 18
  • FDA orphan approvals: 3
  • EU medicines: 3

Recruiting now

Newest posted first, of 33 recruiting on ClinicalTrials.gov ↗

How its trials ended

181 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 51 whose ending is known, 43% met their primary endpoint, 8% missed it and 49% stopped early.

  • Completed, result not reported5329%
  • Ongoing5028%
  • Status unknown2715%
  • Met its primary endpoint2212%
  • Stopped: other or unclear137%
  • Stopped: sponsor or business decision63%
  • Missed its primary endpoint42%
  • Stopped: enrollment or feasibility32%
  • Stopped: safety21%
  • Stopped: lack of efficacy11%

Trials authorized in Canada

The 10 newest of 18; search them all in Canada trials
Sep 2, 2026A phase 2 proof of-concept study with a randomized, double blind, placebo-controlled period, followed by an active treatment extension period to assess the…Seladelpar (GS-2024) / Cilofexor (GS-9674)Gilead SciencesPending
May 25, 2026A phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of elafibranor in adult participants with…Elafibranor (IPN60190)IpsenPending
Jan 13, 2025A 52-week, double-blind, placebo-controlled, randomized, phase 3 study intended to determine the effects of seladelpar on normalization of alkaline phosphatase…SeladelparGilead SciencesClosed
Oct 9, 2024A randomized, double-blind, placebo-controlled, study to evaluate the effect of seladelpar on clinical outcomes in patients with primary biliary cholangitis…Seladelpar (MBX-8025)Gilead SciencesOngoing
Jun 4, 2024A phase 3, open-label, long-term safety extension study evaluating the safety and tolerability of the fixed-dose combination of obeticholic acid and…Obeticholic acid-bezafibrateAlfasigmaClosed
Feb 2, 2024A phase III randomised, parallel-group, double-blind, placebo-controlled, two-arm study to evaluate the efficacy and safety of elafibranor 80 mg on long-term…Elafibranor (IPN60190)IpsenOngoing
Jan 11, 2024A phase 2, randomized, placebo-controlled, parallel group, multicenter 12-week study with a 52-week extension to evaluate the efficacy and safety of two doses…Pemafibrate (K-808)Kowa Research Institute, IncClosed
Nov 14, 2023A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of volixibat in the treatment of cholestatic pruritus in patients with…VolixibatMirum PharmaceuticalsOngoing
Aug 3, 2022Randomized, double-blind, placebo-controlled study to evaluate the effects of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis or…EP547Escient Pharmceuticals IncClosed
Mar 25, 2022A phase 2a, double-blind, randomized, active controlled, parallel group study evaluating the efficacy, safety, and tolerability of bezafibrate administered in…Obeticholic acid / BezafibrateAlfasigmaClosed

FDA orphan designations

Approved first, then open designations, newest first
Mar 17, 2026LynavoyTreatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patientsIntercept Pharmaceuticals, Inc. (A wholly owned subsidiary of Alfasigma S.p.A.)Approved
Aug 14, 2024LivdelziTreatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate…Gilead Sciences, Inc.Approved
Jun 10, 2024IqirvoTreatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate…Ipsen Bioscience Inc.Approved
Jul 24, 2025Selective nonsteroidal FXR agonistTreatment primary biliary cholangitisCascade Pharmaceuticals, IncDesignated
Dec 30, 2024PDC-E2-peptide drug substanceTreatment of primary biliary cholangitisCOUR Pharmaceuticals Development Company, Inc.Designated
Oct 23, 2024VolixibatTreatment of primary biliary cholangitisMirum Pharmaceuticals, Inc.Designated
Jul 25, 2024Navacim, a human-specific peptide-major histocompatibility…Treatment of primary biliary cholangitisParvus Therapeutics U.S., Inc.Designated
Apr 20, 2023PemafibrateTreatment of primary biliary cholangitisKowa Research Institute, Inc.Designated
Jan 12, 2023GolexanoloneTreatment of primary biliary cholangitisUmecrine Cognition ABDesignated
Feb 1, 2021(2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl…Treatment of Primary Biliary CholangitisFuture Medicine Co., Ltd.Designated
Jan 26, 2021Saroglitazar magnesiumTreatment of Primary Biliary Cholangitis (PBC)Zydus Therapeutics Inc.Designated
Oct 16, 2020SetanaxibTreatment of primary biliary cholangitisCalliditas Therapeutics ABDesignated
Mar 30, 2020Combination of p-Tolylmethylcarbinol nicotinic acid ester…Treatment of primary biliary cholangitisRNR BioMedical Inc.Designated
Mar 9, 2020Glucagon-like peptide-1/Glucagon/Gastric inhibitory…Treatment of primary biliary cholangitisHanmi Pharmaceutical Company, Ltd.Designated
Feb 11, 2019BudesonideTreatment of primary biliary cholangitisAsahi Kasei Therapeutics ABDesignated

Medicines authorised in the EU

Newest first
Oct 22, 2026LynavoyLinerixibat · orphanGlaxoSmithKline Trading Services LimitedEMA ↗
Sep 19, 2024IqirvoElafibranor · orphanIpsen PharmaEMA ↗
not availableLyvdelzi (previously Seladelpar Gilead)Seladelpar lysine dihydrate · orphanGilead Sciences Ireland Unlimited CompanyEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.